Zanapezil

Zanapezil (TAK-147) is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC50=51.2 nM) . Zanapezil shows a moderate inhibition of muscarinic M1 and M2 receptor binding with Ki values of 234 and 340 nM, respectively. Zanapezil can be used for the research of early stages of Alzheimer's disease (AD) [1][2].

Product Specifications

CAS Number

[142852-51-5]

Product Name Alternative

TAK-147

UNSPSC

12352005

Target

Cholinesterase (ChE)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/zanapezil.html

Purity

99.63

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C2CCCCNC2=C1)CCC3CCN(CC4=CC=CC=C4)CC3.O=C(O)/C=C/C(O)=O

Molecular Formula

C29H36N2O5

Molecular Weight

492.61

References & Citations

[1]K Hirai, et al. Neurochemical effects of 3-[1- (phenylmethyl) -4-piperidinyl]-1- (2,3,4,5-tetrahydro-1H-1-b enzazepin-8-yl) -1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats. J Pharmacol Exp Ther. 1997 Mar;280 (3) :1261-9.|[2]Izzettin Hatip-Al-Khatib, et al. Comparison of the effect of TAK-147 (zanapezil) and E-2020 (donepezil) on extracellular acetylcholine level and blood flow in the ventral hippocampus of freely moving rats. Brain Res. 2004 Jun 25;1012 (1-2) :169-76.